Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

brentuximab vedotin

Known as: CAC10-1006, cAC10-vcMMAE 
An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab… Expand
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (2)

AdcetrisSGN-35

Broader (1)

Immunoconjugates
NCIt Antineoplastic Agent TerminologyTumor Necrosis Factor Receptor Superfamily Member 8, humanbrentuximab vedotin 50 MG Injection [Adcetris]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
PURPOSE Locally advanced or metastatic urothelial carcinoma is an incurable disease with limited treatment options, especially… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
  • figure 2
Review
2019
Review
2019
Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)
A multitude of new agents for the treatment of hematologic malignancies has been introduced over the past decade. Hematologists… Expand
Review
2019
Review
2019
Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes
Targeted delivery of therapeutic molecules into cancer cells is considered as a promising strategy to tackle cancer. Antibody… Expand
Review
2019
Review
2019
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
BACKGROUND Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was… Expand
Review
2019
Review
2019
Antibodies to watch in 2019
ABSTRACT For the past 10 years, the annual ‘Antibodies to watch’ articles have provided updates on key events in the late-stage… Expand
Highly Cited
2016
Highly Cited
2016
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
Purpose Classical Hodgkin lymphoma (HL) frequently exhibits genetic alterations leading to overexpression of the programmed death… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Highly Cited
2015
Highly Cited
2015
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
BACKGROUND Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Highly Cited
2012
Highly Cited
2012
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
Progress has been made recently in developing antibody-drug conjugates (ADCs) that can selectively deliver cancer drugs to tumor… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2012
Highly Cited
2012
Brentuximab vedotin
In August 2011 brentuximab vedotin (Adcetris; Seattle Genetics), a CD30-specific antibody–drug conjugate, was approved by the US… Expand
Highly Cited
2010
Highly Cited
2010
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
BACKGROUND Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common tumors expressing CD30. Previous… Expand
  • table 1
  • table 3
  • table 4
  • table 5
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE